PMID: 6404547Jun 1, 1983Paper

Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens

Cancer
S E VoglB Bennett

Abstract

Thirty-eight women with advanced ovarian cancer were given monthly cycles of intravenous cyclophosphamide, Adriamycin (doxorubicin) and cis-platin, and oral hexamethylmelamine. Of 26 with tumor which would be evaluated for response, 42% had complete remission and 50% partial remission. Median time to disease progression from entry for all 38 patients was 13 months, and median survival 23.5 months. The bulk of tumor at the time chemotherapy was begun was the only significant prognostic factor for time to disease progression and survival. Of the seven women surviving free of disease a median of three years later, five had no mass greater than 2 centimeters in diameter at entry. Toxicity was predominantly myelosuppression and vomiting, with mild peripheral neuropathy in 27% and no significant renal or cardiac toxicity. The response rate of 92% is much higher than that previously reported with melphalan, and the survival considerably longer. The toxicity is acceptable, given the substantial improvement in results.

Citations

Oct 3, 1999·Seminars in Surgical Oncology·T C Randall, S C Rubin
Jan 1, 1986·Journal of Cancer Research and Clinical Oncology·S R Kempf, S Ivankovic
Jun 1, 1996·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·T BeşeA Gezer
Aug 1, 1995·Critical Reviews in Oncology/hematology·P J Hoskins
Sep 12, 2001·The Surgical Clinics of North America·T C Randall, S C Rubin
Aug 12, 2003·International Journal of Radiation Oncology, Biology, Physics·Selim FiratBeth Erickson
Jan 5, 2002·Journal of the American College of Surgeons·N Gillette-ClovenM F Kohler
Mar 10, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·D. HamidP. Dufour
Mar 10, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·S. Pecorelli, G. Favalli
Feb 13, 2002·Seminars in Oncology·David G Mutch
Feb 21, 1985·The New England Journal of Medicine·G S RichardsonJ H Nelson
May 11, 1999·Obstetrical & Gynecological Survey·C S ChuJ E Wheeler
Jul 2, 2004·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·H Martínez-SaídC M López-Graniel
Dec 7, 1985·British Medical Journal·D Guthrie
Jan 1, 1997·Cancer Investigation·I Benjamin, S C Rubin
Apr 1, 1984·American Journal of Obstetrics and Gynecology·J T WhartonF N Rutledge
Jun 2, 2006·Obstetrics and Gynecology·Snehal Bhoola, William J Hoskins
Nov 1, 1986·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·E M RosenL E Botnick
Jul 4, 2007·Surgical Oncology Clinics of North America·Elizabeth Suh-Burgmann, C Bethan Powell
Dec 1, 1988·European Journal of Cancer & Clinical Oncology·Y KikuchiI Kizawa
Jul 1, 1992·Gynecologic Oncology·R FontanelliE di Re
Oct 1, 1988·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Z HernádiL G Lampé
Jun 1, 1987·European Journal of Cancer & Clinical Oncology·M J PiccartF Muggia
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M E van der BurgG Stoter
Jan 1, 1986·European Journal of Cancer & Clinical Oncology·J Abrams

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.